News
IMMX
10.31
-1.72%
-0.18
Weekly Report: what happened at IMMX last week (0622-0626)?
Weekly Report · 1d ago
All You Need to Know About Immix Biopharma (IMMX) Rating Upgrade to Buy
NASDAQ · 6d ago
Weekly Report: what happened at IMMX last week (0615-0619)?
Weekly Report · 06/22 10:37
Immix Biopharma Analyst Bullish But Flags Safety, Adoption Questions
Benzinga · 06/18 17:38
IMMIX BIOPHARMA INC <IMMX.O>: BOFA GLOBAL RESEARCH INITIATES COVERAGE WITH BUY RATING; PRICE OBJECTIVE $27
Reuters · 06/18 13:51
This Intuit Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday
Benzinga · 06/18 12:10
This Talen Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Benzinga · 06/18 11:45
Immix Biopharma Price Target Announced at $27.00/Share by B of A Securities
Dow Jones · 06/18 10:27
Immix Biopharma Initiated at Buy by B of A Securities
Dow Jones · 06/18 10:27
Immix Biopharma initiated with a Buy at BofA
TipRanks · 06/18 10:22
B of A Securities Initiates Coverage On Immix Biopharma with Buy Rating, Announces Price Target of $27
Benzinga · 06/18 10:17
U.S. RESEARCH ROUNDUP- Datadog, Jabil, Prologis
Reuters · 06/18 07:14
Immix Biopharma Price Target Announced at $19.00/Share by LifeSci Capital
Dow Jones · 06/17 18:48
Immix Biopharma publishes corporate presentation highlighting NXC-201 CAR-T in relapsed/refractory AL amyloidosis
PUBT · 06/17 17:09
Analysts Offer Insights on Healthcare Companies: Opus Genetics (IRD), Immix Biopharma (IMMX) and Haemonetics (HAE)
TipRanks · 06/17 12:01
Immix Biopharma initiated with an Outperform at LifeSci Capital
TipRanks · 06/17 11:50
Weekly Report: what happened at IMMX last week (0608-0612)?
Weekly Report · 06/15 10:37
Weekly Report: what happened at IMMX last week (0601-0605)?
Weekly Report · 06/08 10:32
These 10 small-cap U.S. healthcare companies carry the market's most expensive valuations
Seeking Alpha · 06/02 14:20
Weekly Report: what happened at IMMX last week (0525-0529)?
Weekly Report · 06/01 10:38
More
Webull provides a variety of real-time IMMX stock news. You can receive the latest news about Immix Biopharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About IMMX
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.